Event Info
Program
View or download the Book of abstracts
Below is the preliminary program, which is subject to change by the start of the conference.
List of poster presentations can be found HERE.
Sunday, September 22
| 17:00 - 22:00 |
Participant registration, Shanghai Novotel hotel | |
| 19:30 - 22:00 | Welcome drink | |
Monday, September 23
8:30 - 8:50 Opening ceremony
Plenary Session 1 (大会报告 1) Mon. Sept. 23 星期一上午
Session chairs 主持人: Professor Ao Zhang and Professor Christel Bergström
| 8:50 - 9:30 |
Ao Zhang, Ph.D. Professor, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, and National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, China |
|
| 9:30 - 10:10 | Annette Bauer-Brandl, Professor, University of Southern Denmark Biomimetic in vitro Tools for Mechanistic Insight into Prodrug Performance: Dissolution/Bioconversion/Permeation Studies |
|
| 10:10 - 10:30 | Coffee break + poster presentations | |
| 10:30 - 11:10 | Christel Bergström, Professor, Molecular Pharmaceutics at Uppsala University, Sweden; Adjunct Professor in Pharmaceutics at Monash Institute of Pharmaceutical Sciences, Monash University, Australia New methods for absorption profiling of advanced drug delivery systems |
|
| 11:10 - 11:50 |
Carolina Säll, Ph.D., Principal Scientist. Novo Nordisk, Denmark Can we utilize a small molecule strategy when developing therapeutic peptides? |
|
| 11:50 - 13:30 |
Lunch + poster presentations |
S1 分会报告 1 (Drug design/Drug screening) Mon. Sept. 23 星期一下午
Session chairs 主持人: Dr. Wei Zhu and Dr. Huiping Amy Guan
| 13:30 - 14:00 |
Wei Zhu, Ph.D., Head of Medicinal Chemistry, China Innovation Center of Roche, China Enhancing Precision in Therapeutics: Targeted Drug Delivery via Site-Selective Activation of Prodrug |
|
| 14:00 - 14:30 |
Zhixiong Zhao, Ph.D., CADD Director, Beyang Therapeutics |
|
| 14:30 - 15:00 | Yuanfeng Xia, Ph.D., Executive Director, Head of biology in small molecule discovery department in GenSci Pharma Discovery of a highly potent KIF18A inhibitor for Tumors with Chromosome Instability |
|
| 15:00 - 15:30 | Jingwu Kang, Ph.D. Prof. State Key Laboratory of Chemical Biology, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, China Chemoproteomics and Phosphoproteomics Profiling Reveals Salvianolic Acid A as a Covalent Inhibitor of mTORC1 |
|
| 15:30 - 15:50 |
Coffee break + poster presentations | |
| 15:50 - 16:20 | Huiping Amy Guan, PhD, Chief Technology Officer, Uprotech Pharmaceutical Inc Defining ADMET and DMPK profiling of small molecule drugs based on disease targets |
|
| 16:20 - 16:50 | Haiyan Ying, PhD, Executive director, Discovery Biology, Abbisko Therapeutics, China Irpagratinib (ABSK011) A Potential First/Best-in-Class FGFR4 Inhibitor |
|
| 16:50 - 17:20 |
Anna Karpenko, United Institute of Informatics Problems, National Academy of Sciences of Belarus, Republic of Belarus |
|
| 17:20 - 17:40 | Oral presentations - to be added later |
S2 分会报告 2 (Drug design/Drug screening/PROTAC) Mon. Sept. 23 星期一下午
Session chairs 主持人: Dr. Xiaobao Yang and Dr. Li Zeng
| 13:30 - 14:00 | Weiwen Ying，Ph.D. Founder, CEO, Ranok Therapeutics, China. Chaperone-mediated Protein Degradation technology platform |
|
| 14:00 - 14:30 | Xingquan Ma, Ph.D. Co-president of Chempartner & Head of Chemistry , China Opinions in Integrated TPD/PROTAC Discovery |
|
| 14:30 - 15:00 | Yan Feng, Ph.D. Founder, CEO, LeadingTac Pharma, China IRAK4 Degrader, A Promising Choice for the Treatment of Autoimmune Diseases |
|
| 15:00 - 15:30 | Li Zeng, Ph.D. CEO, Jing Medicine, China. Non-Small Cell Lung Cancer (NSCLC) Treatment and PROTAC as a New Targeted Therapy |
|
| 15:30 - 15:50 |
Coffee break + poster presentations | |
| 15:50 - 16:20 | Yong Cang，Professor, School of Life Science and Technology, Shanghai Tech University；Co-founder and Principal Scientist of Degron Therapeutics, China Targeting the undruggable disease targets with molecular glue degraders |
|
| 16:20 - 16:50 | Jiyue Zhang, Ph.D. Co-founder and CEO, Aubrak Therapeutics, China PROTAC drug development based on tumor tissue-specific E3 ligase |
|
| 16:50 - 17:20 | Wenfu Tan, M.D., Ph.D. Professor, School of Pharmacy, Fudan University, China Development of an oral BCL-XL PROTAC |
|
| 17:20 - 17:50 | Xiaobao Yang, Ph.D. Founder, Chairman and CEO, Gluetacs Therapeutics, China Protein degradation Dual platform (GlueTacs®) driven oncology and autoimmune disease drug development |
|
| 17:50 - 18:10 | Oral presentations - to be added later |
Tuesday, September 24
S3 分会报告 3 (Structures and Physiochemical properties) Tue. Sept. 24 星期二上午
Session chairs 主持人: Dr. Alex Adveef and Professor Tatjana Verbić
| 8:30 - 9:00 | Alex Avdeef, CEO, In ADME Research, USA Glycine.HCl – ‘Uncommon’ Common-Ion Effects in High Ionic-Strength Solutions |
|
| 9:00 - 9:30 | Shenaz Bunally, PhD, Associate Director, GlaxoSmithKline, UK Enhancing Drug Design: The Physicochemical Approach |
|
| 9:30 - 10:00 |
Tatjana Verbić, Professor, University of Belgrade, Serbia |
|
| 10:00–10:20 |
Coffee break + poster presentations |
| 10:20 - 10:50 | Kiyohiko Sugano, Professor, Ritsumeikan University, Japan Cutting the Gordian knot of bicarbonate buffer by floating lid |
|
| 10:50 - 11:20 | Klara Valko, CEO, Biomimetic Chromatography Ltd., UK Analysis of measured biomimetic properties of one thousand marketed drug molecules - comparison of calculated and measured data and general characterisations of the property space |
|
| 11:20 - 11:50 | Hassan Karimi-Maleh, Professor, University of Electronics Science and Technology of China Electrochemical Sensors and biosensors in pharmaceutical and environmental analysis; new principles and research |
|
| 11:50 - 12:10 | Nurhasni Hassan, Faculty of Pharmacy, Hasanuddin University, Jl. Perintis Kemerdekaan KM 10, Makassar 90245, Indonesia Development and Characterization of Clindamycin-releasing Polyvinyl Alcohol with Self-healing Property for the Effective Treatment of Biofilm-Infected Wounds |
|
| 12:10 - 12:30 | Dmitriy Rybin, Udmurt Federal Research Center UB of RAS, Izhevsk, Russian Federation Exploring the mechanisms behind the amorphization and co-amorphization of organic and bioinorganic substances |
|
| 12:30 - 13:30 |
Lunch + poster presentations |
S4 分会报告 4 (CMC and Formulation) Tue. Sept. 24 星期二上午
Session chairs 主持人: Dr. Likun Wang and Dr. Decheng Ma
| 8:30 - 9:00 | Likun Wang, Ph.D.，Founder & Managing Director，Nanjing HaiWei Pharmaceutical Technologies Co., Ltd Predicting crystallization rate of amorphous solid dispersion: a Griseofulvin/HPMCAS case study |
|
| 9:00 - 9:30 | Xueming Liu, Ph.D.Vice President, Chemistry, Manufacturing and Controls, Haihe Biopharma Co. Ltd. The Effects of the Physical Properties of Drug Substance on the Drug Release of Oral Solid Dosage Forms |
|
| 9:30 - 10:00 | Yang Wang, Ph.D. Leader of Technology Platform, Shenzhen HwaGen Pharmaceutical Co., Ltd. Application of Flow Chemistry in Drug Substance Process Development |
|
| 10:00 - 10:20 |
Coffee break + poster presentations |
| 10:20 - 10:50 | Decheng Ma, Ph.D. CEO of Crystal Formulation Services Overcome Solubility Challenges for Oral Solid Dosage Forms (OSD) with Amorphous Solid Dispersion (ASD) |
|
| 10:50 - 11:20 |
Longwei Sun, Ph.D. Director of CMC, Formulation Head, Asieris Pharmaceuticals |
|
| 11:20 - 11:40 | Derar M. Omari, Faculty of Pharmacy/Yarmouk University, Irbid, Jordan Microwave Co - Crystallization of Modafinil with Gelucire 48/16 to improve its compression Characteristics |
|
| 11:40 - 12:00 | Evgeniy Losev, Novosibirsk State University, Novosibirsk, Russia Control over metastable polymorphs of carbamazepine: mechanochemistry and crystallization from fatty acid melt |
|
| 12:00 - 13:30 |
Lunch + poster presentations | |
|
S5 分会报告 5 (ADME and PK) Tue. Sept. 24 星期二下午 |
||
| 13:30 - 14:00 | Dafang Zhong, Ph.D., Professor and PI, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Metabolic and Pharmacokinetic Studies of the Prodrug Vicagrel |
|
| 14:00 - 14:30 |
Wei Li, Ph. D., Founder and CEO, Tianjin Ruicheng Jianda Medical Technology Co., Ltd |
|
| 14:30 - 15:00 | Zhenyu Guo, PhD., Associate Director Application Science, TandemAI Revolutionizing Drug Discovery: The Role of Advanced Virtual High-Throughput Screening and Cryptic Pocket Identification in Hit Identification |
|
| 15:00 - 15:20 | Coffee break + poster presentations | |
| 15:20 - 15:40 |
Zhuohan Hu, PhD., CEO, Professor, Research Institute for Liver Diseases (Shanghai)Co.,Ltd |
|
| 15:40 - 16:00 | Hong-Can Ren, Ph.D., Director Genfleet, China The risk prediction and management of Drug-Drug Interaction in drug discovery and development |
|
| 16:00 - 16:30 | Zhengdan Zhu, Ph.D., Drug Discovery Scientist & Head of Computational Chemistry, DP Technology Attempts in the AI for Science Era to Optimize Drug-Like Properties: Pre-Trained Models, Fine-Tuning, and Data Mining |
|
| 16:30 - 17:00 | Hang Fai Kwok, PhD., Professor, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau S.A.R. Polyamidoamine dendrimer conjugated with novel scorpion venom peptide as a promising targeted delivery system for glioblastoma |
|
| 17:00 - 17:20 | Yury Kornoushenko, Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, Republic of Belarus Structure-based virtual screening of potential SARS-CoV-2 entry inhibitors based on lichen metabolites |
|
|
S6 分会报告 6 (Pharmacology and PK/PD/PBPK modeling) Tue. Sept. 24 星期二下午 |
||
| 13:30 - 14:00 | Xiaoqiang Xiang, Ph.D., Professor, School of Pharmacy, Fudan University, China Progress of drug-drug interaction research in China based on PBPK model |
|
| 14:00 - 14:30 | Xiaomei Zhuang Ph.D., Research fellow of the Beijing Institute of Pharmacology and Toxicology Advancing Drug Development: Bridging the Gap Between Animal Studies and Human Applications with PBPK Modeling |
|
| 14:30 - 15:00 | Hua He Ph.D., Associate Professor of China Pharmaceutical University PBPK Modeling and Simulation: A Key to Predicting Drug Efficacy and Toxicity |
|
| 15:00 - 15:20 |
Coffee break + poster presentations | |
| 15:20 - 15:50 | Dongyang Liu, Ph.D., Professor & Director of Clinical Pharmacology and Pharmacometrics Office (CPPO), and Deputy Director of Drug Clinical Trial Center of Peking University Third Hospital (PUTH) MIPD Study for Specific Population: Our progression and thinking |
|
| 15:50 - 16:10 | Kirill Peskov, M&S Decisions, Dubai, UAE Re-thinking clinical translation in Immuno-Oncology: A QSP platform for the analysis of syngeneic murine tumor dynamics data |
|
| 16:10 - 16:30 | W.S. Fred Wong, National University of Singapore, Singapore Developing calcaratarin D, a labdane diterpenoid, as therapeutics for chronic lung diseases |
|
| 16:30 - 16:50 | Danila Varabyeu, United Institute of Informatics Problems, National Academy of Sciences of Belarus, Minsk,Republic of Belarus Application of graphically accelerated molecular docking to reinforcement learning for de novo design of potential HIV-1 entry inhibitors |
|
| 16:50 - 17:10 | Anna Gonchar, United Institute of Informatics Problems, National Academy of Sciences of Belarus, Minsk, Republic of Belarus Computational discovery of small-molecule compounds as potential inhibitors of Mycobacterium tuberculosis enoyl acyl carrier protein reductase (InhA) |
|
|
Wedensday, September 25 S7 分会报告 7 (Toxicology/Safety/Drugability assessments) Wed. Sept. 25 星期三上午 |
||
| 8:30 - 9:00 | Yun Zhang, Ph.D., DABT, DSTL, Pfizer, USA Developing Non-Clinical Safety Assessment Strategy for New Drug Development |
|
| 9:00 - 9:30 | Jieyu Dai, PhD，Associate Director, Preclinical Sciences and Translational Safety, Johnson & Johnson, China Assessment and Mitigation Strategy for Reactive Metabolite in Drug Discovery |
|
| 9:30 - 10:00 | Xu Zhang，Ph.D., Vice President, ICE Bioscience InC Assessment of Abuse Potential of Benzodiazepines, Diazepam with ICESTP Drug Abuse Safety Panel |
|
| 10:00 - 10:20 | Coffee break + poster presentations | |
| 10:20 - 10:50 | Xiancheng Zeng, Ph.D., VP, Preclinical Toxicology Research of Medicilon Safety assessment of preclinical candidates - An analysis and comparison of NOAEL/MTD and safety windows between rodents and non-rodents |
|
| 10:50 - 11:20 | Liqiang Zhou, Ph.D., DCST, DABT, Director of Toxicology, JOINN Laboratories (Suzhou) Co,. Ltd Nonclinical Considerations for Proteolysis-Targeting Chimeras (PROTACs) |
|
| 11:20 - 11:50 | Li Ma, Senior Principal Scientific Researcher, Genentech, USA Dynamic Free Fraction: Concept, Methodology and Impact on Hepatic Clearance Prediction Using the Well-stirred Model |
|
| 11:50 - 12:10 | Yan Laikou, United Institute of Informatics Problems , National Academy of Sciences of Belarus, Minsk, Republic of Belarus Virtual screening and identification of potential HIV-1 entry inhibitors targeting the NHR domain of the viral gp41 glycoprotein using a drug repurposing strategy |
|
| 12:10 - 13:30 | Lunch + poster presentations | |
|
S8 分会报告 8 (CNS and Translational Sciences) Wed. Sept. 25 星期三上午 |
||
| 8:30 - 9:00 | Jashvant (Jash) D. Unadkat, Ph.D. Professor Dept. of Pharmaceutics Univ. of Washington, US In vitro predictions, followed by verification through PET imaging, of human CNS distribution and drug-drug interactions of transported drugs |
|
| 9:00 - 9:30 | Wandong Zhang, Principal Research Officer, National Research Council Canada; Adjunct Professor, University of Ottawa, Canada CNS delivery for challenging modalities |
|
| 9:30 - 10:00 | Yanyan Zhang，Ph.D. Senior Director Clinical Pharmacology, AstraZeneca China In silico prediction of brain penetration |
|
| 10:00 - 10:20 | Coffee break + poster presentations | |
| 10:20 - 10:50 | Houfu Liu，Ph.D. Vice President, Clinical Pharmacology/DMPK, SciNeuro Therapeutics Inc Drug Distribution into Peripheral Nerve |
|
| 10:50 - 11:20 | Tingting Fu，MSc., MBA Executive Director DMPK, Safety Assessment, Clinical Pharmacology and Regulatory Affairs, Suzhou Zanrong Pharma Limited Discovery and development of CNS penetrant cancer drugs |
|
| 11:20 - 11:50 | Irena Loryan, M.D. and Ph.D., Senior lecturer Pharmacokinetics and an associate professor in the Department of Pharmacy, Uppsala University, Sweden Drug transport across CNS and PNS barriers |
|
| 11:50 - 12:10 | Yuhua Song, Departments of 1Biomedical Engineering Washington University School of Medicine, St. Louis, MO. USA Repurposing Available Drugs to target immune receptor TREM2 in Alzheimer’s Disease |
|
| 12:10 - 13:30 | Lunch + poster presentations | |
|
Plenary Session 2 (大会报告 2) Wed. Sept. 25 星期三下午 |
||
| 13:30 - 14:10 |
Ning Jiao, Ph.D., Professor, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, China Late-Stage Modification of Bioactive Molecules for Drug Discovery |
|
| 14:10 - 14:50 |
Defang Ouyang, Profesor, Ph.D., PI, Institute of Chinese Medical Sciences, University of Macau |
|
| 14:50 - 15:10 | Coffee break + poster presentations | |
| 15:10 - 15:50 | Godefridus J. Peters, Profesor, Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands Mechanisms of action of the novel epigenetic modulator fluorocyclopentenylcytosine (RX-3117); activation, resistance and DNMT1 downregulation |
|
| 15:50 - 16:30 | Tonglei Li, Professor, Purdue University, USA, Editor-in-Chief of Pharmaceutical Research Encoding Quantum Information of Molecule for Drug Properties Prediction |
|
| 16:30 - 17:10 |
Weikang Tao, Ph.D., MD, Corp VP and General Manager of Global R&D of Innovative Medicines, Qilu Pharmaceuticals |
|
| 17:10 - 17:40 | Closing ceremony | |